Drug Profile
E6 TCR
Alternative Names: anti-HPV-16 E6 TCR; HPV-16 E6 TCR gene therapyLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Kite Pharma; National Cancer Institute (USA)
- Class Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anal cancer; Cervical cancer; Oropharyngeal cancer; Penile cancer; Vulvovaginal cancer
Most Recent Events
- 03 Oct 2017 Gilead Sciences acquired Kite Pharma
- 29 Jun 2017 National Cancer Institute plans a phase I trial for Cervical intraepithelial neoplasia in USA (NCT03197025)
- 02 Jun 2017 Adverse events and efficacy data from a phase II trial in HPV-associated Anal cancer, Cervical cancer, Oropharyngeal cancer, Penile cancer, Vulvovaginal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)